Axial T1-weighted (A) and STIR (B) images depict denervation edemalike signal of extensor muscles of dorsal and mobile wad compartments with no fatty infiltration or atrophy consistent with NS-RADS M1.

Neuropathy Score Reporting and Data System (NS-RADS) Subclass M1 (Edemalike Signal): Axial T1-weighted (A) and STIR (B) images depict denervation edemalike signal of extensor muscles of dorsal and mobile wad compartments with no fatty infiltration or atrophy consistent with NS-RADS M1.


March 4, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), a new reporting and data system for standardized evaluation and recording of peripheral nerve pathologies—Neuropathy Score Reporting and Data System (NS-RADS)—has been created and validated in a multicenter study.

“The proposed NS-RADS classification is accurate and reliable across different reader experience levels and a spectrum of peripheral neuropathy conditions,” wrote lead researcher Avneesh Chhabra of UT Southwestern in Dallas, TX. “NS-RADS can be used as a standardized guideline for reporting peripheral neuropathies and improved multidisciplinary communications.”

Chhabra and team’s retrospective study included 100 patients with nerve imaging examinations and known clinical diagnoses. Utilizing mutually agreed-upon qualitative benchmarks for classifying and grading peripheral neuropathies, different classes were established to account for the spectrum of underlying pathologies (unremarkable, injury, neoplasia, entrapment, diffuse neuropathy, not otherwise specified, and postintervention state) with subclasses to describe lesion severity or extent. Validation was performed by 11 fellowship-trained musculoskeletal radiologists across 10 institutions, and after initial multimedia training, all 100 cases were blind-presented to readers.

Offering a uniform lexicon and practical guideline for reporting neuropathic conditions on MRI, ultimately, NS-RADS accuracy for determining milder versus more severe categories per radiologist ranged from 88% to 97% for nerve lesions and from 86% to 94% for muscle abnormalities.

“On the basis of the overall promising interrater agreement shown in this study, we believe that the newly proposed NS-RADS classification will perform as well in routine practice as it did in this initial validation study,” the authors of this AJR article concluded. 

For more information: arrs.org


Related Content

News | Radiology Education

Sept. 16, 2026 — As urgent care centers and outpatient healthcare facilities expand their use of diagnostic imaging, the ...

Time September 17, 2026
arrow
News | PET Imaging

Sept. 10, 2026 — Siemens Healthineers Molecular Imaging has completed a $43.6 million construction and renovation ...

Time September 14, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

A radiologist pulls up a chest CT scan flagged for a pulmonary nodule. One artificial intelligence (AI) tool writes its ...

Time September 09, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Aug. 26, 2026 — AMRA Medical has announced the publication of new research in Neurology demonstrating the potential of ...

Time August 26, 2026
arrow
News | Radiology Business

August 18, 2026 – NewVue, a provider of cloud-native software that unifies how radiologists work while improving ...

Time August 25, 2026
arrow
News | Radiology Imaging

Aug. 13, 2026 — Epic's new Care Everywhere Diagnostic Image Exchange allows health systems using Epic to share ...

Time August 21, 2026
arrow
News | Cardiac Imaging

Aug. 20, 2026 – The novel, radiopaque, polymer-based embolic coil from Embolization, Inc. has now surpassed 125 implants ...

Time August 20, 2026
arrow
Feature | Artificial Intelligence | Madhu Jahagirdar

Radiologists spend much of their day moving between different systems: One application to review images. Another to ...

Time August 17, 2026
arrow
News | X-Ray

Aug. 10, 2026 — Teledyne Technologies Inc. and Varex Imaging Corp. have jointly announced that they have entered into a ...

Time August 14, 2026
arrow
News | FDA

Aug. 1, 2026 — Candelis recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance ...

Time August 13, 2026
arrow
Subscribe Now